ChemoCentryx Revenue vs. Working Capital

CCXIDelisted Stock  USD 51.99  0.00  0.00%   
Based on the key profitability measurements obtained from ChemoCentryx's financial statements, ChemoCentryx may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in May. Profitability indicators assess ChemoCentryx's ability to earn profits and add value for shareholders.
For ChemoCentryx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ChemoCentryx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ChemoCentryx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ChemoCentryx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ChemoCentryx over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
Please note, there is a significant difference between ChemoCentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine if ChemoCentryx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ChemoCentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ChemoCentryx Working Capital vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ChemoCentryx's current stock value. Our valuation model uses many indicators to compare ChemoCentryx value to that of its competitors to determine the firm's financial worth.
ChemoCentryx is the top company in revenue category among related companies. It is number one stock in working capital category among related companies reporting about  1.78  of Working Capital per Revenue. Comparative valuation analysis is a catch-all model that can be used if you cannot value ChemoCentryx by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ChemoCentryx's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ChemoCentryx's earnings, one of the primary drivers of an investment's value.

ChemoCentryx Revenue vs. Competition

ChemoCentryx is the top company in revenue category among related companies. Market size based on revenue of Biotechnology industry is currently estimated at about 39.61 Billion. ChemoCentryx adds roughly 37.28 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.

ChemoCentryx Working Capital vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

ChemoCentryx

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
37.28 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

ChemoCentryx

Working Capital

 = 

Current Assets

-

Current Liabilities

 = 
66.54 M
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

ChemoCentryx Working Capital Comparison

ChemoCentryx is currently under evaluation in working capital category among related companies.

ChemoCentryx Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ChemoCentryx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ChemoCentryx will eventually generate negative long term returns. The profitability progress is the general direction of ChemoCentryx's change in net profit over the period of time. It can combine multiple indicators of ChemoCentryx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc. ChemoCentryx operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 178 people.

ChemoCentryx Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ChemoCentryx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ChemoCentryx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ChemoCentryx's important profitability drivers and their relationship over time.

Use ChemoCentryx in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoCentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoCentryx will appreciate offsetting losses from the drop in the long position's value.

ChemoCentryx Pair Trading

ChemoCentryx Pair Trading Analysis

The ability to find closely correlated positions to ChemoCentryx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoCentryx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoCentryx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoCentryx to buy it.
The correlation of ChemoCentryx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoCentryx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoCentryx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoCentryx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ChemoCentryx position

In addition to having ChemoCentryx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electronics Thematic Idea Now

Electronics
Electronics Theme
Companies manufacturing electronic appliances and goods. The Electronics theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in ChemoCentryx Stock

If you are still planning to invest in ChemoCentryx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ChemoCentryx's history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Transaction History
View history of all your transactions and understand their impact on performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges